Evidence mapPaperPMID 31162713Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2019

Modelling potential cost savings from use of real-time continuous glucose monitoring in pregnant women with Type 1 diabetes.

H R Murphy, D S Feig, J J Sanchez, S de Portu, A Sale, CONCEPTT Collaborative Group

Abstract read
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Advances in Continuous Glucose Monitoring: Clinical Applications.Endocrinology and metabolism (Seoul, Korea) · 2025
    Review
  7. Article
  8. The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. The Benefits Of Continuous Glucose Monitoring In Pregnancy.Endocrinology and metabolism (Seoul, Korea) · 2023
    Review
  14. Roadmap to the Effective Use of Continuous Glucose Monitoring in Pregnancy.Diabetes spectrum : a publication of the American Diabetes Association · 2023
    Article
  15. Review
  16. Review
  17. Time in Range in Pregnancy: Is There a Role?Diabetes spectrum : a publication of the American Diabetes Association · 2021
    Article
  18. Article
  19. Time in range centered diabetes care.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

H R MurphyNorwich Medical School, University of East Anglia, Norwich.ORCID 0000-0001-6876-8727
D S FeigMt Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0001-8561-7584
J J SanchezSunnybrook Research Institute, Toronto, Ontario, Canada.
S de PortuMedtronic International Trading Sàrl, Tolochenaz, Switzerland.ORCID 0000-0001-8651-4982
A SaleMedtronic Ltd, Watford, UK.
CONCEPTT Collaborative Group

Funding

Department of Health CDF-2013-06-035
6 · The paper itself

Abstract

aimTo investigate potential cost savings associated with the use of real-time continuous glucose monitoring (RT-CGM) throughout pregnancy in women with Type 1 diabetes.

methodsA budget impact model was developed to estimate, from the perspective of National Health Service England, the total costs of managing pregnancy and delivery in women with Type 1 diabetes using self-monitoring of blood glucose (SMBG) with and without RT-CGM. It was assumed that the entire modelled cohort (n = 1441) would use RT-CGM from 10 to 38 weeks' gestation (7 months). Data on pregnancy and neonatal complication rates and related costs were derived from published literature, national tariffs, and device manufacturers.

resultsThe cost of glucose monitoring was £588 with SMBG alone and £1820 with RT-CGM. The total annual costs of managing pregnancy and delivery in women with Type 1 diabetes were £23 725 648 with SMBG alone, and £14 165 187 with SMBG and RT-CGM; indicating potential cost savings of approximately £9 560 461 from using RT-CGM. The principal drivers of cost savings were the daily cost of neonatal intensive care unit (NICU) admissions (£3743) and the shorter duration of NICU stay (mean 6.6 vs. 9.1 days respectively). Sensitivity analyses showed that RT-CGM remained cost saving, albeit to lesser extents, across a range of NICU costs and durations of hospital stay, and with varying numbers of daily SMBG measurements.

conclusionsRoutine use of RT-CGM by pregnant women with Type 1 diabetes, would result in substantial cost savings, mainly through reductions in NICU admissions and shorter duration of NICU care.

Indexed as

Cost SavingsBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1EnglandFemaleHumansHyperbilirubinemiaHypoglycemiaInfant, NewbornIntensive Care, NeonatalIntensive Care Units, NeonatalLength of StayPregnancyPregnancy in DiabeticsPremature BirthBlood Glucose

Identifiers

PMID31162713
PMCPMC6900078

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.